SAMSUNG-ELECTRONICS
30.11.2021 11:02:08 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced three of its latest automotive chip solutions; the Exynos Auto T5123 for 5G connectivity, the Exynos Auto V7 for comprehensive in-vehicle infotainment systems, and the ASIL-B certified S2VPS01 power management IC (PMIC) for the Auto V series.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005513/en/
“Smarter and more connected automotive technologies for enriched in-vehicle experiences including entertainment, safety and comfort are becoming critical features on the road,” said Jaehong Park, Executive Vice President of System LSI Custom SOC Business at Samsung Electronics. “With an advanced 5G modem, an AI-enhanced multi-core processor, and a market-proven PMIC solution, Samsung is transfusing its expertise in mobile solutions into its automotive lineup and is positioned to expand its presence within the field.”
Exynos Auto T5123: The Industry’s First 5G Connectivity Solution for Automobiles
The Exynos Auto T5123 is a 3GPP Release 15 telematics control unit specifically designed to bring fast and seamless 5G connectivity in both standalone (SA) and non-standalone (NSA) mode to the next generation of connected cars. It delivers essential information to the vehicle in real-time via high-speed download of up to 5.1 gigabits per second (Gbps) and allows passengers to enjoy a host of new services such as high-definition content streaming and video calls on the go.
To efficiently process large amounts of data transmitted and received through the 5G modem, the Exynos Auto T5123 supports a high speed PCIe (PCI Express) interface and a low-power high-performance LPDDR4x mobile DRAM. In addition, the unit comes with two Cortex-A55 CPU cores and a built-in Global Navigation Satellite System (GNSS) to minimize the use of external ICs and help reduce product development time. The T5123 meets stringent requirements for automotive components and is Automotive Electronics Council-Q100 (AEC-Q100) qualified.
The Exynos Auto T5123 is currently in mass production and is delivering 5G-based vehicle communication capabilities for the first time in the industry.
Exynos Auto V7: A Powerful Processor for IVI Systems in Mid to High-end Vehicles
The Exynos Auto V7 is the newest addition to Samsung’s automotive-brand processor lineup and is designed for in-vehicle infotainment systems. For powerful processing performance, the V7 integrates eight 1.5-gigahertz (GHz) Arm Cortex-A76 CPU cores and 11 Arm Mali G76 GPU cores. The GPU comes in two separate groups, with three cores in the ‘small’ domain for cluster display and AR-HUD, and eight in the ‘big’ domain for central information display (CID) and others. Such physical separation allows the GPU to support multiple systems simultaneously and brings safer operation as it keeps one domain from interfering with another. In addition to its powerful CPU and GPU, the V7 is equipped with an NPU for convenient services such as virtual assistance that can process visual and audio data for face, speech or gesture recognition features.
For a safer and more enjoyable driving experience, the Exynos Auto V7 supports up to four displays and 12 camera inputs that provide information to assist drivers and passengers. The V7’s imaging system provides bad pixel correction, dynamic range compression and geometric distortion correction to provide noiseless and distortion-free images for features like surround view and parking assistance. For immersive in-car entertainment, the chip comes with three HiFi 4 audio processors that deliver excellent audio quality for songs, movies and even games on the go. To run all these features as smoothly as possible, the V7 has up to 32 gigabytes (GB) of LPDDR4x memory capacity that offers high bandwidth of up to 68.3 gigabytes per second (GB/s).
The Exynos Auto V7 also offers strong data protection through an isolated security processor for crypto operation and provides a hardware key using a one-time programmable (OTP) or physical unclonable function (PUF). Furthermore, for critical functional safety, the Exynos Auto V7 complies with ASIL-B requirements of safety support for a digital cluster and an embedded safety island that detect and manage faults to maintain a safe state with a fault management unit (FMU).
The Exynos Auto V7 is currently in mass production and is being used in Volkswagen’s latest In-Car Application-Server (ICAS) 3.1, developed by LG Electronics’ VS (Vehicle component Solutions) division, to power their next-generation in-vehicle infotainment system.
S2VPS01 – An ASIL-B Certified Power Management IC for the Exynos Auto V Series
The S2VPS01 is a PMIC specifically designed and developed for the Exynos Auto V9 and V7. It is Samsung’s first automotive solution produced under the ISO 26262 functional safety process certification that was acquired in 2019, and it also achieved an ASIL-B certification in 2021.
An Automotive Safety Integrity Level (ASIL), specified under ISO 26262, ranges from A to D, with D being the highest level. The Level is assigned by analyzing and assessing the severity, exposure and controllability of vehicle operations in a number of environments. To ensure the safety of vehicle systems, ASIL-B compliance is becoming a key requirement for automotive OEMs and their Tier 1 suppliers when selecting partners and solutions.
The S2VPS01 regulates and rectifies the flow of electrical power, allowing reliable and robust in-vehicle infotainment system performance. It is comprised of highly efficient triple/dual-phase buck converters, and integrates a low-dropout regulator (LDO) and real-time clock (RTC) within the package. For protection from harsh thermal and electrical conditions, the power IC comes with various protection functions including over voltage protection (OVP), under voltage protection (UVP), short circuit protection (SCP), over current protection (OCP), thermal shut down (TSD), clock monitoring, and output stuck checks.
For more information about Samsung’s Exynos products, please visit http://www.samsung.com/exynos .
# # #
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005513/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom